SCHEMBL29615083

SCHEMBL29615083

C#Cc1cccc(Nc2ncnc3cc(OC)c(N)cc23)c1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 15/20 0.83
GAK O14976 3/20 0.83
FBP1 P09467 2/20 0.83
ALDH1A1 P00352 1/20 0.83
MAPT P10636 1/20 0.83
ABCG2 Q9UNQ0 2/20 0.69
ERBB2 P04626 6/20 0.69
RET P07949 3/20 0.69
KDR P35968 3/20 0.69
ILK Q13418 2/20 0.69
RIPK2 O43353 2/20 0.69
BUB1 O43683 2/20 0.69
STK10 O94804 2/20 0.69
ABL1 P00519 2/20 0.69
LCK P06239 2/20 0.69
LYN P07948 2/20 0.69
SRC P12931 2/20 0.69
FGFR2 P21802 2/20 0.69
FECH P22830 2/20 0.69
FLT3 P36888 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3422491 1.00 EGFR (0.83) EGFRGAKFBP1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL28197803 0.99 EGFR (0.82) EGFRGAKFBP1ALDH1A1MAPT
SCHEMBL667895 0.91 EGFR (1.00) EGFRGAKFBP1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL1507455 0.90 EGFR (0.98) EGFRGAKFBP1ALDH1A1MAPT
SCHEMBL14862082 0.89 FBP1 (0.84) EGFRGAKFBP1ALDH1A1MAPT
SCHEMBL20127269 0.89 EGFR (0.85) EGFRGAKFBP1ALDH1A1MAPT
SCHEMBL15946889 0.88 EGFR (0.85) EGFRGAKFBP1ALDH1A1MAPT
SCHEMBL644810 0.87 EGFR (0.83) EGFRGAKFBP1ALDH1A1MAPT
SCHEMBL1507690 0.87 EGFR (0.83) EGFRGAKFBP1ALDH1A1MAPT
SCHEMBL1507609 0.86 EGFR (0.78) EGFRGAKFBP1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435045-B2 Tyrosine kinase inhibitors and pharmaceutical application thereof JIANGSU CONCORD BIOTECHNOLOGY CO., LTD (CN) 2025-10-07 US disclosed
CN-114394942-B Tyrosine kinase inhibitor and pharmaceutical application thereof 江苏康可得生物技术股份有限公司 2024-12-10 CN disclosed
WO-2022184119-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL USE THEREOF 江苏康可得生物技术股份有限公司 2022-09-09 WO disclosed
CN-114394942-A Tyrosine kinase inhibitor and pharmaceutical application thereof 江苏康可得生物技术股份有限公司 2022-04-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435045-B2 Tyrosine kinase inhibitors and pharmaceutical application thereof SRC, ABL1, ERBB2 EGFR 9/4885GAK 300/4885FBP1 2523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.